Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma

Gastroenterology. 2024 Sep 14:S0016-5085(24)05461-1. doi: 10.1053/j.gastro.2024.09.009. Online ahead of print.
No abstract available